Retia Medical Receives FDA Clearance for Argos Infinity Cardiovascular Intelligence Platform
核心洞察
The FDA has granted 510(k) clearance for Retia Medical (搜索)'s Argos Infinity (搜索), a cardiovascular intelligence software platform designed for high-risk surgical and critical care environments.
The platform analyzes real-time physiologic data from existing monitoring systems to support earlier recognition of hemodynamic instability in operating rooms and intensive care units.
Nearly 70% of low cardiac index time in cardiac surgery patients occurs while blood pressure remains normal, highlighting the need for advanced monitoring capabilities.
The U.S. Food and Drug Administration has granted 510(k) clearance for Retia Medical (搜索)'s Argos Infinity (搜索), a cardiovascular intelligence software platform designed to enhance patient monitoring in high-risk surgical and critical care environments across health systems. The clearance, announced on February 17, 2026, enables broader deployment of the technology that transforms routine physiologic data into actionable cardiovascular insights.
Advanced Monitoring for Early Detection
Argos Infinity (搜索) builds on Retia's clinically validated Multi-Beat Analysis (MBA) algorithm and analyzes real-time physiologic data streams from existing monitoring and tele-ICU systems. The platform addresses a critical gap in patient care by supporting earlier recognition of hemodynamic instability in operating rooms and intensive care units, where high-risk patients often begin to deteriorate before changes appear in standard vital signs.
In cardiac surgery patients, nearly 70% of low cardiac index time occurs while blood pressure remains normal, according to the company. This delayed recognition can drive ICU escalation and organ injury, including acute kidney injury (AKI). The timing of this FDA clearance is particularly significant as AKI is included as a hospital harm measure tied to reimbursement under CMS quality programs beginning with the 2026 reporting period, affecting reimbursement in 2027.
"In high-risk patients, deterioration can begin before traditional vital signs clearly reflect it," said Chiedozie Udeh, MD, MHEcon, MBA, FCCM, FASA, Professor of Anesthesiology and Medical Director, Cleveland Clinic eHospital. "By analyzing the monitoring data we already collect, Argos Infinity (搜索) expands visibility into patients' cardiovascular status across surgical settings and critical care units without requiring additional bedside hardware."
Expanding Digital Care Environment
Marc Zemel, Chief Executive Officer of Retia Medical (搜索), emphasized the platform's integration capabilities. "FDA clearance of Argos Infinity (搜索) marks an important step in extending reliable cardiovascular insight beyond individual devices and into the broader digital care environment," Zemel said. "Hospitals already collect vast amounts of physiologic data. Infinity analyzes those existing data streams to deliver consistent hemodynamic intelligence across operating rooms and intensive care units, without requiring replacement of current monitoring infrastructure."
Clinical Validation and Deployment
Argos Infinity (搜索) has been deployed under IRB approval across more than 400 beds in multi-hospital tele-ICU environments, where it operates on top of existing digital monitoring platforms. With FDA clearance, Retia can now expand that deployment beyond research settings. The software applies Retia's Multi-Beat Analysis algorithm, which has been validated in 14 peer-reviewed clinical publications and demonstrated reliable performance in complex conditions including arrhythmia, low cardiac output states, and unstable blood pressure.
The platform complements Retia's Argos Cardiac Output Monitor, extending the same patented algorithmic foundation from the bedside to high-risk surgical and critical care environments across health systems. In the United States, the Argos monitor is distributed by Medtronic plc.
Technology Foundation
Retia Medical (搜索)'s technology is built on its patented Multi-Beat Analysis algorithm, originally developed at MIT and Michigan State University. The company focuses on transforming routine physiologic data into reliable, actionable hemodynamic insight through software-based integration with existing monitoring and tele-ICU systems. The technology has been validated across 75 hospitals and is designed to perform reliably in complex and unstable patients while enabling broader access through existing infrastructure.